Conmed (NYSE:CNMD) reported Q2 EPS of $0.76, $0.01 better than the analyst estimate of $0.75. Revenue for the quarter came in at $277.2 million versus the consensus estimate of $274.25 million.
GUIDANCE:
Due to changes in foreign exchange rates, the Company is lowering its revenue guidance for the full year 2022 and now expects revenue between $1.095 billion and $1.140 billion compared to its prior guidance of between $1.105 billion and $1.150 billion. Based on recent exchange rates, the Company now expects foreign exchange to have a 100 to 150 bps negative impact on full-year 2022 revenue growth.
The Company now expects full-year 2022 adjusted diluted net earnings per share in the range of $3.40 to $3.55, down from the prior range of $3.50 to $3.65 to account for a $0.10 currency headwind.